Interview with Viktor Shafranskyi, General Manager, IPSEN Ukraine
Ipsen has showed some very positive results worldwide in 2010 and so far this year, specifically in non-Western European markets that grew by 12% in 2010. How have the Ukrainian…
Address: 36 Pushkinskaya street, O1004, Kiev,Ukraine
Tel: 380445026529
Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.1 billion in 2010. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by four franchises: neurology / Dysport®, endocrinology / Somatuline®, uro-oncology / Decapeptyl® and hemophilia. Moreover, the Group has an active policy of partnerships. R&D is focused on innovative and differentiated technological patient-driven platforms, peptides and toxins. In 2010, R&D expenditure totaled more than €220 million, above 20% of Group sales. The Group has total worldwide staff of close to 4,500 employees.
Ipsen started its activities in Ukraine 20 years ago, with the promotion of a group of legacy products, the majority of which were dedicated to the treatment of gastrointestinal diseases. A couple of years later, Ipsen introduced its innovative franchise, whose three main therapeutic areas are in oncology, endocrinology, and for the treatment of neuro-muscular disorders. For the moment, the company’s strategic focus is to expand its innovative franchise and to push these medicines forward into the market.
Over the past seven years, the range of strategic products in Ipsen’s Ukraine portfolio has more than doubled. At the beginning of 2004, about 30% of sales came from the innovative franchise, whereas by the end of this year, around 60% of sales is expected to be generated by innovative medicines.
In both its targeted therapeutic areas and primary care, Ipsen has a diversified portfolio of leading drugs.
The Group’s product portfolio includes pharmaceutical products marketed around the world to specialists working in its targeted therapeutic areas (oncology, endocrinology, neurology, hematology), which are its primary areas of development. The Group also markets products in other therapeutic areas in which it boasts longstanding expertise (gastroenterology, cardiovascular and cognitive disorders). To a large extent, these are composed of primary care.
Ipsen has showed some very positive results worldwide in 2010 and so far this year, specifically in non-Western European markets that grew by 12% in 2010. How have the Ukrainian…
Igor Bondarenko of Ukraine’s Dnipro State Medical University, Evgeny Levenko from clinical trials company, ARENSIA, and Olena Popova from IQVIA offer their perspectives on maintaining quality and ensuring participant protection…
The March edition of DIA’s Global Forum magazine features a special section on clinical research in Ukraine, over one year on from the beginning of the Russian invasion. Here, Chieko…
The March edition of DIA’s Global Forum magazine features a special section on clinical research in Ukraine, over one year on from the beginning of the Russian invasion. Anina Adelfio…
Russia’s invasion of Ukraine has been roundly condemned by the pharmaceutical industry and almost all Big Pharmas have pledged humanitarian support to Ukraine. However, not all companies have followed the…
Ukraine’s bold decision to outsource public procurement of medicines to international agencies to combat rampant corruption has been well received by the pharma MNCs operational in the country, but faces…
Vladimir Sayenko, founding partner, and Anzhela Makhinova, counsel, of the leading Ukrainian law firm Sayenko Kharenko, give an overview on the Ukrainian pharmaceutical industry in 2017 and explain the expansion…
Tetiana Korotchenko, Country Representative of Crown Agents, one of the three international organizations contracted by the Ukrainian government to temporarily handle healthcare procurement and put an end to the plague…
Dmytro Popov, the owner, founder and CEO Elfa Group, Ukraine’s leading cosmetics manufacturer, provides his insight into Elfa’s 20-year presence in the Ukrainian market, the company’s international growth strategies and…
Dr. Maxim Sokolov, chief external specialist of the Ministry of Health of Ukraine in cardiology, principal scientist of the Department of Interventional Cardiology of the National Academy of Medical Sciences…
Dr. Paul Melekhov, vice president Eastern Europe at Pharmascience, Canada’s third largest generic company, provides insights into the unique history of Pharmascience in Ukraine and the pioneering market approach that…
Julia Sidorova, country manager of Alvogen, a new international player to the Ukrainian market, provides insights into the targeted strategy that Alvogen employs throughout the world and how this is…
Victoria Filatova, president and chairperson of the Association of Perfumery and Cosmetics of Ukraine (APCU), discusses her strategic priorities, the association’s main achievements in its six years of existence, and…
See our Cookie Privacy Policy Here